2026 Global: Antifungal Drugs-Competitive Review (2032) report
Description
The 2026 Global: Antifungal Drugs-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antifungal drugs by geography and historical trend. The scope of the report extends to sizing of the antifungal drugs market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Abbott Laboratories, Astellas Pharma, Bayer, GlaxoSmithKline (GSK), Merck, Novartis, Pfizer, Sanofi, Gilead Sciences, and SCYNEXIS are among the ten major companies with prominent antifungal drug portfolios and active roles in antifungal R&D and commercialization. Abbott’s broad anti-infective offerings and hospital-focused formulations contribute to its presence in antifungal markets, while Astellas has established products such as micafungin and has transferred rights for Mycamine in strategic deals. Bayer’s long-standing global pharmaceutical operations include antifungal agents across topical and systemic classes, and GSK’s recent collaboration to commercialize novel agents like ibrexafungerp (Brexafemme) highlights its active role in expanding antifungal treatment options.
Merck and Pfizer remain influential through established antifungal therapies and extensive global distribution networks that support both branded and generic antifungal availability. Novartis, including through its Sandoz generics division and transactions involving antifungal assets, plays a significant role in hospital and outpatient antifungal supply chains. Sanofi and Gilead Sciences are credited among leading firms due to their broader anti-infective and specialty portfolios that intersect with antifungal development and market presence. Glenmark and other large generics manufacturers also supply widely used topical and systemic antifungals, contributing to accessibility and price competition in many markets.
SCYNEXIS represents a smaller, innovation-focused company that has advanced first-in-class agents addressing resistant fungal infections, exemplified by regulatory approvals and licensing agreements that brought ibrexafungerp to broader commercial partners. Across these ten companies, strategic activity includes new drug approvals (including agents for invasive candidiasis and vulvovaginal candidiasis), licensing and acquisition of antifungal brands, and partnerships to commercialize novel mechanisms of action aimed at overcoming resistance and improving formulations. Market drivers shaping these companies’ antifungal strategies include rising invasive fungal infections, emergence of resistant species such as Candida auris, growth in prophylactic and hospital use of echinocandins and azoles, and the expanding role of generics and specialty biotech collaborations in delivering both established and next‑generation antifungal therapies.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antifungal drugs by geography and historical trend. The scope of the report extends to sizing of the antifungal drugs market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Abbott Laboratories, Astellas Pharma, Bayer, GlaxoSmithKline (GSK), Merck, Novartis, Pfizer, Sanofi, Gilead Sciences, and SCYNEXIS are among the ten major companies with prominent antifungal drug portfolios and active roles in antifungal R&D and commercialization. Abbott’s broad anti-infective offerings and hospital-focused formulations contribute to its presence in antifungal markets, while Astellas has established products such as micafungin and has transferred rights for Mycamine in strategic deals. Bayer’s long-standing global pharmaceutical operations include antifungal agents across topical and systemic classes, and GSK’s recent collaboration to commercialize novel agents like ibrexafungerp (Brexafemme) highlights its active role in expanding antifungal treatment options.
Merck and Pfizer remain influential through established antifungal therapies and extensive global distribution networks that support both branded and generic antifungal availability. Novartis, including through its Sandoz generics division and transactions involving antifungal assets, plays a significant role in hospital and outpatient antifungal supply chains. Sanofi and Gilead Sciences are credited among leading firms due to their broader anti-infective and specialty portfolios that intersect with antifungal development and market presence. Glenmark and other large generics manufacturers also supply widely used topical and systemic antifungals, contributing to accessibility and price competition in many markets.
SCYNEXIS represents a smaller, innovation-focused company that has advanced first-in-class agents addressing resistant fungal infections, exemplified by regulatory approvals and licensing agreements that brought ibrexafungerp to broader commercial partners. Across these ten companies, strategic activity includes new drug approvals (including agents for invasive candidiasis and vulvovaginal candidiasis), licensing and acquisition of antifungal brands, and partnerships to commercialize novel mechanisms of action aimed at overcoming resistance and improving formulations. Market drivers shaping these companies’ antifungal strategies include rising invasive fungal infections, emergence of resistant species such as Candida auris, growth in prophylactic and hospital use of echinocandins and azoles, and the expanding role of generics and specialty biotech collaborations in delivering both established and next‑generation antifungal therapies.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.